Delamanid
Brand: Deltyba (global)
Antibiotic
Anti-TB (nitro-dihydro-imidazooxazole)
Pharmacokinetics
| Half-life | 38 hours |
| Tmax | 4 h |
| Bioavailability | 45 % (approx) |
| Protein Binding | 99 % |
| Volume of Distribution | 0.2 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | yes |
| Notes | QT prolongation risk ↑ when combined with other QT drugs; avoid high-fat meal. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
QT prolongation, GI upset, hypokalemia
Contraindications:
Baseline QT prolongation, severe hepatic disease
Precautions:
Close ECG monitoring; correct electrolytes; avoid QT prolonging combinations